Previous 10 | Next 10 |
Meridian Bioscience (NASDAQ: VIVO ) provides preliminary Q2 sales and revised FY 2019 guidance. More news on: Meridian Bioscience, Inc., Healthcare stocks news, Read more ...
CINCINNATI, April 02, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidan...
CINCINNATI, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR. These master mixes offe...
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Welltower Inc. (NYSE:WELL), Ferrari N.V. (NYSE:RACE), Caesars Entertai...
Meridian Bioscience, Inc. (VIVO) Q1 2019 Earnings Conference Call January 24, 2019 09:00 AM ET Company Participants Jack Kenny - Chief Executive Officer Eric Rasmussen - Chief Financial Officer Conference Call Participants William Quirk - Piper Jaffray Catherine Schulte - R...
The following slide deck was published by Meridian Bioscience Inc. in conjunction with their 2019 Q1 earnings Read more ...
Meridian Bioscience ( VIVO ) Q1 results : Revenues: $51.5M (-1.5%). More news on: Meridian Bioscience Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Meridian Bioscience (NASDAQ: VIVO ): Q1 Non-GAAP EPS of $0.20 beats by $0.03 ; GAAP EPS of $0.19 beats by $0.02 . More news on: Meridian Bioscience Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CINCINNATI, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019 Highlights: Total revenue decreased 1.5% to $51.5 million, as compared to $52.3 million in the f...
The following slide deck was published by Meridian Bioscience Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...